Skip to content
Search
home button

CTTI

LoginJoin Our Newsletter
  • Who We Are
    • Who We Are
    • Transforming Trials 2030
      • Join Transforming Trials 2030
    • Organizational Structure
      • Executive Committee
        • Mark B McClellan, MD, PhD
        • John Alexander, MD, MHS, FACC
        • M. Khair ElZarrad, PhD, MPH
        • Donna R. Cryer, JD
        • Pat Furlong
        • Steven K. Galson, MD, MPH
        • Patricia Hurley, MSC
        • Michael Kolodziej, MD
        • Theodore Lystig, PhD, MS
        • Rod MacKenzie, PhD
        • Pierre Meulien, PhD
        • Robert Temple, MD
        • Spiros Vamvakas, MD
        • Bram Zuckerman, MD
      • Steering Committee
      • Staff
    • Membership
      • Benefits & Responsibilities
      • Annual Membership Fees
      • Become A Member
      • Become a Patient/Caregiver Rep
    • Annual Accomplishments
    • Funding
    • Transparency
  • Our Work
    • Our Work
       All Recommendations & Resources
    • Quality
      • Quality By Design
      • Informing ICH E6 Renovation
      • Diversity
      • ClinicalTrials.gov Reporting Challenges
      • Recruitment
      • Pregnancy Testing
      • State of Clinical Trials
      • Clinical Trials Issues Related to COVID-19
      • Engaging All Stakeholders in Clinical Trial Design
    • Digital Health Trials
      • Developing Novel Endpoints
      • Planning Decentralized Trials
      • Selecting and Testing a Digital Health Technology
      • Managing Data
      • Supporting Sites
      • Interacting with Regulators
    • Novel Clinical Trial Designs
      • Real-World Data
      • Disease Progression Modeling
      • Master Protocol Studies
      • Trials in Health Care Settings
      • Antibacterial Drug Development
        • ABDD HABP/VABP Studies
        • ABDD Peds Trials
        • ABDD Streamlining HABP/VABP Trials
        • ABDD Unmet Need
      • Registry Trials
      • Electronic Healthcare Data
      • Large Simple Trials
    • Patient Engagement
      • Patient Group Engagement
      • Patient Engagement Collaborative
    • Investigators and Sites
      • Investigator Community
      • Investigator Qualification
      • Study Start-Up
    • Ethics and Human Research Protection
      • Single IRB
      • Informed Consent
      • Safety Reporting
      • Data Monitoring Committees
  • Newsroom
    • Newsroom
    • CTTI History
    • CTTI News
    • Publications
    • Webinars
    • Media Coverage
    • CTTI Meetings
    • Press Releases
    • Case Studies
    • CTTI Presentations
  • Contact us
  • Training Videos

Digital Health Trials: Recommendations for Delivering an Investigational Product

News

Home - Digital Health Trials: Recommendations for Delivering an Investigational Product

Posted on July 8, 2021July 8, 2021 by Laura Shannon

Digital Health Trials: Recommendations for Delivering an Investigational Product

Digital Health Trials: Recommendations for Delivering an Investigational Product

This entry was posted in Delivering an Investigational Product, Recommendation. Bookmark the permalink.

Post navigation

← Study Start-Up Timelines: Identifying Challenges & Opportunities for Change
Digital Health Trials: Recommendations for Interacting with Regulators →
 
Search
  • Who We Are
  • Our Work
  • Newsroom
  • Contact us
 
DISCLAIMER: CTTI encourages the use of all materials listed on this site in the pursuit of improving the clinical trials enterprise. Our recommendations, tools, meeting summaries, and more are available to the public for free. We do ask that you acknowledge the source whenever using or referencing CTTI materials. Read our Citation Policy.

Our Work Topics

Quality

Patient Engagement

Investigators and Sites

Digital Health Trials

Novel Clinical Trial Designs

Ethics and Human Research Protection

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.